About Sarepta Therapeutics, Inc.
Sarepta develops gene therapies for Duchenne muscular dystrophy and other neuromuscular diseases. No dividend, high beta, binary FDA and clinical catalyst risk. Rich CSP premiums but regulatory decisions create extreme gaps. Biotech-level volatility demands conservative strike placement.
Biotechnology